PriceTargets.com logo

Oak Street Health - OSH Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$39.00 As of 05/2/2023 01:00 AM ET
+0 (0.00%)
Get New Oak Street Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OSH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OSH

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Oak Street Health in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $39.00.

This chart shows the closing price for OSH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Oak Street Health. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/21/2023Wolfe ResearchDowngradeOutperform ➝ Market Perform
3/15/2023TD CowenReiterated RatingOutperform ➝ Market Perform$34.00 ➝ $39.00
2/23/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$35.00 ➝ $39.00
2/15/2023Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$35.00 ➝ $39.00
2/9/2023Raymond JamesDowngradeOutperform ➝ Market Perform
2/9/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
2/9/2023William BlairDowngradeOutperform ➝ Market Perform
2/8/2023Truist FinancialDowngradeBuy ➝ Hold
2/8/2023Leerink PartnersBoost TargetMarket Perform$33.00 ➝ $39.00
2/8/2023Piper SandlerDowngradeOverweight ➝ Neutral$47.00 ➝ $39.00
2/8/2023Stifel NicolausDowngradeBuy ➝ Hold
2/7/2023Stifel NicolausBoost TargetBuy ➝ Hold$35.00 ➝ $39.00
1/12/2023Raymond JamesUpgradeMarket Perform ➝ Outperform$35.00
1/10/2023Leerink PartnersBoost TargetMarket Perform$23.00 ➝ $33.00
1/6/2023UBS GroupLower TargetNeutral$28.00 ➝ $21.00
11/21/2022Raymond JamesDowngradeOutperform ➝ Market Perform
11/14/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight
11/10/2022Leerink PartnersLower TargetMarket Perform$32.00 ➝ $23.00
11/9/2022Canaccord Genuity GroupLower Target$32.00 ➝ $27.00
9/12/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$32.00 ➝ $29.00
8/31/2022Morgan StanleyBoost TargetEqual Weight$19.00 ➝ $30.00
8/9/2022Evercore ISIBoost Target$37.00
8/9/2022CowenBoost Target$34.00
8/8/2022BarclaysBoost TargetOverweight$31.00 ➝ $34.00
8/4/2022Leerink PartnersBoost TargetMarket Perform$23.00 ➝ $32.00
8/3/2022UBS GroupBoost TargetNeutral$26.00 ➝ $28.00
7/27/2022Stifel NicolausBoost Target$25.00 ➝ $35.00
7/26/2022ArgusInitiated CoverageHold
6/15/2022Bank of AmericaDowngradeBuy ➝ Underperform$26.00 ➝ $18.00
5/26/2022Sanford C. BernsteinInitiated CoverageOutperform$60.00 ➝ $26.00
5/26/2022Stifel NicolausInitiated CoverageBuy$25.00
4/20/2022UBS GroupInitiated CoverageNeutral$26.00
4/19/2022BarclaysBoost TargetOverweight$27.00 ➝ $31.00
3/29/2022GuggenheimInitiated CoverageNeutral
3/21/2022The Goldman Sachs GroupLower TargetBuy$68.00 ➝ $37.00
3/17/2022CowenUpgradeMarket Perform ➝ Outperform$25.00 ➝ $30.00
3/2/2022Canaccord Genuity GroupLower Target$49.00 ➝ $29.00
3/2/2022Morgan StanleyBoost TargetEqual Weight$18.00 ➝ $19.00
3/2/2022Leerink PartnersBoost TargetMarket Perform$17.00 ➝ $23.00
3/2/2022Piper SandlerLower TargetOverweight$47.00 ➝ $43.00
2/22/2022Leerink PartnersLower TargetMarket Perform$41.00 ➝ $17.00
1/19/2022Truist FinancialLower Target$45.00 ➝ $34.00
1/18/2022Raymond JamesLower TargetOutperform$60.00 ➝ $35.00
1/11/2022Piper SandlerLower Target$55.00 ➝ $47.00
1/10/2022CowenDowngradeOutperform ➝ Market Perform$48.00 ➝ $25.00
12/17/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$44.00 ➝ $33.00
12/16/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$44.00 ➝ $33.00
11/12/2021Morgan StanleyLower TargetOverweight$60.00 ➝ $44.00
11/10/2021Leerink PartnersLower TargetMarket Perform$51.00 ➝ $41.00
10/20/2021Jefferies Financial GroupInitiated CoverageBuy$50.00
10/13/2021Truist FinancialLower TargetBuy$72.00 ➝ $55.00
9/27/2021Leerink PartnersInitiated CoverageMarket Perform$51.00
9/9/2021CowenInitiated CoverageOutperform$61.00
9/8/2021The Goldman Sachs GroupInitiated CoverageBuy$76.00
9/7/2021Robert W. BairdInitiated CoverageOutperform$60.00
8/31/2021Morgan StanleyLower TargetOverweight$79.00 ➝ $60.00
8/12/2021Raymond JamesLower TargetOutperform ➝ Outperform$70.00 ➝ $60.00
8/12/2021BarclaysInitiated CoverageOverweight$71.00
5/21/2021Sanford C. BernsteinInitiated CoverageOutperform$79.00
4/20/2021Cantor FitzgeraldInitiated CoverageOverweight$75.00
3/15/2021Evercore ISIInitiated CoverageOutperform$75.00
3/12/2021Morgan StanleyBoost TargetOverweight$73.00 ➝ $79.00
2/17/2021Piper SandlerBoost Target$59.00 ➝ $69.00
2/12/2021Morgan StanleyBoost TargetOverweight$64.00 ➝ $73.00
1/28/2021Wolfe ResearchInitiated CoverageOutperform$62.00
1/6/2021BTIG ResearchInitiated CoverageNeutral
12/18/2020Truist FinancialBoost Target$60.00 ➝ $72.00
12/17/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$50.00 ➝ $64.00
12/9/2020Raymond JamesInitiated CoverageOutperform$65.00
11/11/2020Piper SandlerReiterated RatingOverweight$54.00 ➝ $59.00
11/11/2020Robert W. BairdBoost TargetOutperform$55.00 ➝ $60.00
11/11/2020Leerink PartnersBoost TargetOutperform$55.00 ➝ $78.00
9/24/2020Leerink PartnersInitiated CoverageOutperform$55.00
9/17/2020Piper SandlerReiterated RatingOverweight$54.00
8/31/2020Truist FinancialInitiated CoverageBuy$56.00
8/31/2020JPMorgan Chase & Co.Initiated CoverageOverweight$52.00
8/31/2020Robert W. BairdInitiated CoverageOutperform$55.00
8/31/2020William BlairInitiated CoverageOutperform
8/31/2020Morgan StanleyInitiated CoverageEqual Weight$50.00
8/31/2020The Goldman Sachs GroupInitiated CoverageBuy$66.00
8/31/2020Piper SandlerInitiated CoverageOverweight$54.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

-0.84 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/2/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/31/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Oak Street Health logo
Oak Street Health, Inc., together with its subsidiaries, offers healthcare services to the patients in the United States. The company operates primary care centers for Medicare beneficiaries. As of December 31, 2021, it operated 129 centers in 19 states, including Illinois, Michigan, Pennsylvania, Ohio, and Texas. The company was founded in 2012 and is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $39.00
Low: $39.00
High: $39.00

50 Day Range

MA: $37.57
Low: $34.57
High: $39.00

52 Week Range

Now: $39.00
Low: $13.29
High: $39.00

Volume

N/A

Average Volume

5,760,056 shs

Market Capitalization

$9.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Oak Street Health?

The following Wall Street research analysts have issued reports on Oak Street Health in the last year:
View the latest analyst ratings for OSH.

What is the current price target for Oak Street Health?

0 Wall Street analysts have set twelve-month price targets for Oak Street Health in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Oak Street Health in the next year.
View the latest price targets for OSH.

What is the current consensus analyst rating for Oak Street Health?

Oak Street Health currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for OSH.

What other companies compete with Oak Street Health?

Other companies that are similar to Oak Street Health include LifeStance Health Group, Privia Health Group, GeneDx, U.S. Physical Therapy and The Pennant Group. Learn More about companies similar to Oak Street Health.

How do I contact Oak Street Health's investor relations team?

Oak Street Health's physical mailing address is 30 W. MONROE ST. STE. 1200, CHICAGO IL, 60603. The company's listed phone number is 844-871-5650 and its investor relations email address is [email protected]. The official website for Oak Street Health is www.oakstreethealth.com. Learn More about contacing Oak Street Health investor relations.